SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic...
SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
About this item
Full title
Author / Creator
Li, Chenguang , Zhang, Jie , Xue, Mei , Li, Xiaoyu , Han, Fei , Liu, Xiangyang , Xu, Linxin , Lu, Yunhong , Cheng, Ying , Li, Ting , Yu, Xiaochen , Sun, Bei and Chen, Liming
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Hyperglycaemia associated with myocardial oxidative stress and fibrosis is the main cause of diabetic cardiomyopathy. Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor has recently been reported to improve glycaemic control in patients with type 2 diabetes in an insulin-independent manner. The aim of this study was to investigate th...
Alternative Titles
Full title
SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_4ba6523e673b443a95b9427ec8314d14
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_4ba6523e673b443a95b9427ec8314d14
Other Identifiers
ISSN
1475-2840
E-ISSN
1475-2840
DOI
10.1186/s12933-019-0816-2
